Simplify Logo

Full-Time

Medical Monitor

Posted on 6/25/2024

Fractyl Health, Inc

Fractyl Health, Inc

51-200 employees

Therapies for Type 2 Diabetes

Biotechnology
Healthcare

Senior, Expert

Burlington, MA, USA

This position may require up to 25% travel.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Communications
Requirements
  • MD or equivalent required
  • Minimum of 5 years direct experience in the medical device industry
  • Proficient with ICH Good Clinical Practice guidelines
  • Experience in type 2 diabetes and/or metabolic disorders
  • Strong interpersonal and communication skills
  • Experience using electronic documentation management system
  • Ability to work independently or with a team
Responsibilities
  • Work as primary Medical Monitor for assigned clinical trials
  • Develop and/or review medical monitoring and safety plans
  • Provide final review and approval of safety narrative
  • Conduct literature reviews for regulatory submissions
  • Consult with stakeholders to assist in the development of clinical trials
  • Work closely with the clinical team to develop/edit clinical documents
  • Perform all activities in compliance with regulations and company policies

Fractyl Health focuses on creating therapies for Type 2 Diabetes (T2D) and obesity, targeting the root causes of these metabolic diseases. Their main product, Rejuva, is a gene therapy platform aimed at improving the function of pancreatic islet cells, which are essential for blood sugar regulation. By enhancing these cells, Fractyl hopes to achieve long-term remission for patients with T2D and obesity. Currently, Rejuva is in preclinical development and has received a CE mark for commercial availability in Europe, although it is still awaiting full FDA approval. Unlike many competitors, Fractyl's approach centers on gene therapy to address the underlying issues of these diseases rather than just managing symptoms. The company's goal is to transform the treatment landscape for T2D and obesity, ultimately preventing and eliminating these conditions.

Company Stage

IPO

Total Funding

$395.4M

Headquarters

Lexington, Kentucky

Founded

2010

Growth & Insights
Headcount

6 month growth

3%

1 year growth

20%

2 year growth

15%
Simplify Jobs

Simplify's Take

What believers are saying

  • Fractyl's innovative approach to metabolic diseases could revolutionize treatment paradigms, offering significant career growth opportunities in a pioneering field.
  • The appointment of experienced leaders like Adrian Kimber and Dr. Timothy Kieffer strengthens the company's strategic and scientific capabilities, enhancing its market positioning.
  • Successful IPO and promising preclinical results for Rejuva indicate strong financial backing and potential for substantial market impact.

What critics are saying

  • The success of Fractyl Health is heavily dependent on the regulatory approval and commercial adoption of its therapies, which are still in preclinical or early clinical stages.
  • The competitive landscape for diabetes and obesity treatments is intense, with numerous established players and emerging startups vying for market share.

What makes Fractyl Health, Inc unique

  • Fractyl Health focuses on gene therapy for Type 2 Diabetes and obesity, targeting the root causes of these diseases, unlike many competitors who focus on symptom management.
  • Their flagship product, Rejuva, aims to enhance pancreatic islet cell function, offering a potential long-term remission solution for T2D and obesity.
  • The company has achieved a CE mark for Rejuva, indicating compliance with stringent health and safety standards in the European Economic Area, setting it apart from competitors still in investigational stages.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE